Comprehensive marketing research of the global pharmaceutical market of drugs for the management of prostate cancer pathologies and assessment of the market potential forecast for domestic manufacturers
DOI:
https://doi.org/10.14739/2409-2932.2026.1.337874Keywords:
prostate cancer, antitumor drugs, pharmaceutical market, marketing studies, assortment analysis, structural analysis, pharmacoeconomic evaluation, market potential, pharmaceutical assistanceAbstract
Given the significant incidence of prostate cancer (PC) among Ukrainian men, it is critical to study the state of pharmaceutical support to ensure proper and effective disease management. The analysis of the distribution of 47 drugs by countries of origin, including leaders such as India (29.8 %), Germany (19.1 %) and Ukraine (12.8 %), indicates the uneven geographical impact and variety of types of drugs – from original to generic. The dynamics of prices, which increased by 2–6 % in 2025 compared to previous years, reflect the impact of inflation and imported factors. This context emphasizes the need for a comprehensive study of the pharmaceutical market to support domestic producers and to ensure the availability of therapy.
The aim of the study was to carry out a marketing analysis of drugs registered in the pharmaceutical market of Ukraine as of April – August 2025, which are used for the management of PC, with the subsequent assessment of nomenclature, origin, forms of release, price correlation and pharmacoeconomic aspects.
Materials and methods. The study is based on the State Register of Medicines of Ukraine, the National Cancer Register, information from the web resources Compendium, apteka911.ua, Tabletki.ua and other sites-aggregators, as well as the unified clinical protocol of the Ministry of Health of Ukraine and the International Instruction of the European Association of Urology and National Comprehensive Cancer Network. Methods of information search, comparative, analytical and marketing analysis, correlation, pharmacoeconomic analysis have been applied. To conduct pharmacoeconomic analysis (Cost-Effectiveness Analysis method, Cost-Minimization Analysis method), prices in pharmacy chains for the period April – August 2025 and reimbursement program data were taken into account.
Results. Analysis of 47 oncological drugs for the treatment of PC as of August 2025 revealed India’s leadership (29.8 %, 14 generics), Germany (19.1 %, 9 original and generics) and Ukraine (12.8 %, 6 generics). In total, 68.0 % of drugs are generics, 32.0 % are original, mainly from the United Kingdom and the United States (6.4 %, 3 drugs). Prices increased by 2–6 % in 2025 compared to 2024.
Conclusions. The study confirmed the dominance of generics (68 %) in the PC market in 2025, with India leadership (29.8 %) and a significant contribution of Ukraine (12.8 %), which increases availability. Germany (19.1 %), the United Kingdom and the United States (6.4 %) provide original drugs, but their high cost requires subsidizing. The rise in prices by 2–6 % emphasizes the importance of local production in Ukraine, where 1.19 million cancer patients are registered. EAU and NCCN support the use of analyzed drugs, which indicates their clinical relevance.
References
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors – a systematic review. Eur Urol. 2023;84(2):191-206. doi: https://doi.org/10.1016/j.eururo.2023.04.021
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi: https://doi.org/10.3322/caac.21834
Ukrainian cancer registry statistics. [Cancer in Ukraine, 2021-2022. Incidence, mortality, prevalence and other relevant statistics]. Bulletin of National Cancer Registry of Ukraine. 2023;24 [cited 2025 Aug 18]. Ukrainian. Available from: http://www.ncru.inf.ua/publications/BULL_24/PDF_E/bull_eng_24.pdf
Kukuruza H, Kukhar M, Lesyk M, Liubchenko O. Analiz vplyvu na VVP ta derzhavni finansy zakhvoriuvanosti na rak peredmikhurovoi zalozy ta yakosti yoho likuvannia v Ukraini [Analysis of the impact of prostate cancer incidence and treatment quality on GDP and state finances in Ukraine]. Ukrainskyi medychnyi chasopys. 2023;(5):1-7. Ukrainian. doi: https://doi.org/10.32471/umj.1680-3051.157.248119
Ziuzin VO, Saveliev AO, Tuzova OV, Frolov YA, Muntian LY. [Analysis of the Incidence of Prostate Cancer and the State of the Organization of Oncological Care for Patients in Ukraine]. Ukrainskyi zhurnal medytsyny, biolohii ta sportu. 2022;7(4):83-8. Ukrainian. doi: https://doi.org/10.26693/jmbs07.04.083
Ukrainian cancer registry statistics. [Cancer in Ukraine, 2020-2021. Incidence, mortality, prevalence and other relevant statistics]. Bulletin of National Cancer Registry of Ukraine. 2022;23 [cited 2025 Aug 18]. Ukrainian. Available from: http://www.ncru.inf.ua/publications/BULL_23/index_e.htm
Tymoshenko AV. [Features of the impact of metabolic syndrome on the prostate cancer aggressiveness]. Klinichna onkolohiia. 2023;13(2):1-4. Ukrainian. doi: https://doi.org/10.32471/clinicaloncology.2663-466X.50-2.30779
Ministry of Health of Ukraine. [On approval of the Lists of medicines and medical devices subject to reimbursement under the program of state guarantees of medical care for the population, as of February 26, 2025]. Order dated 2025 Mar 13, no. 440. Available from: https://moz.gov.ua/storage/uploads/0ff673ad-91df-44c8-a25d-6261a8d915ac/dn_440_13032025_dod.pdf
Cabinet of Ministers of Ukraine. [Some issues of availability of medicines subject to reimbursement in 2025]. Resolution dated on 2024 Dec 3, no. 1380. Available from: https://zakon.rada.gov.ua/laws/show/1380-2024-%D0%BF?lang=en#Text
Prohrama "Dostupni liky" ["Affordable Medicines" Program]. Kyiv: Natsionalna sluzhba zdorovia Ukrainy; 2025 [cited 2025 Aug 18]. Ukrainian. Available from: https://nszu.gov.ua/dostupni-liky.
Ukrainian cancer registry statistics. [Cancer in Ukraine, 2022-2023. Incidence, mortality, prevalence and other relevant statistics]. Bulletin of National Cancer Registry of Ukraine. 2024;25 [cited 2025 Aug 18]. Ukrainian. Available from: http://www.ncru.inf.ua/publications/BULL_25/PDF/BULL_25.pdf
Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State register of medicines of Ukraine] [cited 2025 Aug 18]. Available from: http://www.drlz.kiev.ua
Eccher A, Dei Tos AP, Scarpa A, L'Imperio V, Munari E, Troncone Get al. Cost analysis of archives in the pathology laboratories: from safety to management. J Clin Pathol. 2023;76(10):659-63. doi: https://doi.org/10.1136/jcp-2023-209035
Albright RH, Fleischer AE. A Primer on Cost-Effectiveness Analysis. Clin Podiatr Med Surg. 2024;41(2):313-21. doi: https://doi.org/10.1016/j.cpm.2023.07.006
Soloviov SO, Stakhovsky EO, Leleka MV, Hladkykh FV. [Cost minimization and budget impact analysis of the use of a new 6-month form of triptorelin in the treatment of patients with prostate cancer in Ukraine]. Farmatsevtychnyi zhurnal. 2022;77(6):40-52. Ukrainian. doi: https://doi.org/10.32352/0367-3057.6.22.05
Standart nastanova. Derzhavna otsinka medychnykh tekhnolohii dlia likarskykh zasobiv [Standard guideline. State health technology assessment for medicinal products]. ST-N MOZU 42-9.1:2021. Kyiv; 2021. Ukrainian.
Bushuieva IV, Yerenko OK. Farmakoekonomika u farmacii [Pharmacoeconomics in pharmacy]. Zaporizhzhia: ZSMU; 2020. Ukrainian.
Kileieva OP, Bushuieva IV. [Рharmacoeconomic aspects of the potential consumption of medicinal cosmetics and cosmetics including salicylic acid]. Health & Education. 2023;(4):108-16. Ukrainian. doi: https://doi.org/10.32782/health-2023.4.17
Kileieva OP. [Marketing research and pharmacoeconomic aspects of medicinal cosmetic products containing azelaic acid]. Current issues in pharmacy and medicine: science and practice. 2019;12(1):91-6. Ukrainian. doi: https://doi.org/10.14739/2409-2932.2019.1.159164
eHealth - elektronna systema okhorony zdorovia Ukrainy [eHealth - electronic healthcare system of Ukraine] [cited 2025 Aug 18]. Ukrainian. Available from: https://ehealth.gov.ua
Tabletki.ua - poshukova systema likars’kykh zasobiv v aptekakh Ukrainy [Tabletki.ua – search engine for medicinal products in Ukrainian pharmacies] [cited 2025 Aug 18]. Ukrainian. Available from: https://tabletki.ua
Ministry of Health of Ukraine. Standart medychnoi dopomohy "Rak peredmikhurovoi zalozy" [Standard of medical care "Prostate cancer"]. Order dated 2023 Jun 22, No. 1141. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2023/06/2023_06_14_kn-_rpz-compressed.pdf
Poliakova D. [How to improve the diagnosis and treatment of patients with prostate cancer in Ukraine? Results of the 2023 survey]. Klinichna onkolohiia. 2023;13(4):1-5. Ukrainian. doi: https://doi.org/10.32471/clinicaloncology.2663-466X.52-4.31546
Novi mozhlyvosti dlia likuvannia raku peredmikhurovoi zalozy z vysokym ryzykom prohresuvannia: vysnovok derzhavnoi otsinky medychnykh tekhnolohii [New opportunities for the treatment of prostate cancer with a high risk of progression: conclusion of the state health technology assessment]. 2025 Jan 15 [cited 2025 Aug 12]. Kyiv: Derzhavnyi ekspertnyi tsentr MOZ Ukrainy; 2025. Ukrainian. Available from: https://www.dec.gov.ua/news/novi-mozhlyvosti-dlya-likuvannya-raku-peredmihurovoyi-zalozy-z-vysokym-ryzykom-progresuvannya-u-doroslyh-cholovikiv-opublikovano-vysnovok-z-derzhavnoyi-omt/ (accessed 02.09.2025).
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 M. V. Parchenko, I. V. Bushuieva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
